EPISODE · Jun 27, 2018 · 11 MIN
Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)
from ASCO Education
Rami Manochakian, M.D., a thoracic clinical oncologist at the Mayo Clinic in Florida, presents information on the recently approved drug in oncology, durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC) after the completion of radiation therapy.
Embed this episode
NOW PLAYING
Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)
0:00
11:04
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of ASCO Education?
This episode is 11 minutes long.
When was this ASCO Education episode published?
This episode was published on June 27, 2018.
Can I download this ASCO Education episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!